10779/rcsi.10782275.v1
Christian Ott
Christian
Ott
Melvin D. Lobo
Melvin D.
Lobo
Paul A. Sobotka
Paul A.
Sobotka
Felix Mahfoud
Felix
Mahfoud
Alice V. Stanton
Alice V.
Stanton
John Cockcroft
John
Cockcroft
Neil Sulke
Neil
Sulke
Eamon Dolan
Eamon
Dolan
Markus van der Giet
Markus
van der Giet
Joachim Hoyer
Joachim
Hoyer
Stephen S. Furniss
Stephen S.
Furniss
John P. Foran
John P.
Foran
Adam Witkowski
Adam
Witkowski
Andrzej Januszewicz
Andrzej
Januszewicz
Danny Schoors
Danny
Schoors
Konstantinos Tsioufis
Konstantinos
Tsioufis
Benno J. Rensing
Benno J.
Rensing
Manish Saxena
Manish
Saxena
Benjamin Scott
Benjamin
Scott
G André Ng
G André
Ng
Stephan Achenbach
Stephan
Achenbach
Roland E. Schmieder
Roland E.
Schmieder
Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension.
Royal College of Surgeons in Ireland
2019
Arteriovenous Shunt
Surgical
Blood Pressure
Blood Pressure Monitoring
Ambulatory
Female
Follow-Up Studies
Humans
Hypertension
Iliac Artery
Iliac Vein
Male
Middle Aged
Prospective Studies
Treatment Outcome
Clinical Pharmacology and Therapeutics
2019-11-22 16:18:57
Journal contribution
https://repository.rcsi.com/articles/journal_contribution/Effect_of_Arteriovenous_Anastomosis_on_Blood_Pressure_Reduction_in_Patients_With_Isolated_Systolic_Hypertension_Compared_With_Combined_Hypertension_/10782275
BACKGROUND: Options for interventional therapy to lower blood pressure (BP) in patients with treatment-resistant hypertension include renal denervation and the creation of an arteriovenous anastomosis using the ROX coupler. It has been shown that BP response after renal denervation is greater in patients with combined hypertension (CH) than in patients with isolated systolic hypertension (ISH). We analyzed the effect of ROX coupler implantation in patients with CH as compared with ISH.
METHODS AND RESULTS: The randomized, controlled, prospective ROX Control Hypertension Study included patients with true treatment-resistant hypertension (office systolic BP ≥140 mm Hg, average daytime ambulatory BP ≥135/85 mm Hg, and treatment with ≥3 antihypertensive drugs including a diuretic). In a post hoc analysis, we stratified patients with CH (n=31) and ISH (n=11). Baseline office systolic BP (177±18 mm Hg versus 169±17 mm Hg, P=0.163) and 24-hour ambulatory systolic BP (159±16 mm Hg versus 154±11 mm Hg, P=0.463) did not differ between patients with CH and those with ISH. ROX coupler implementation resulted in a significant reduction in office systolic BP (CH: -29±21 mm Hg versus ISH: -22±31 mm Hg, P=0.445) and 24-hour ambulatory systolic BP (CH: -14±20 mm Hg versus ISH: -13±15 mm Hg, P=0.672), without significant differences between the two groups. The responder rate (office systolic BP reduction ≥10 mm Hg) after 6 months was not different (CH: 81% versus ISH: 82%, P=0.932).
CONCLUSIONS: Our data suggest that creation of an arteriovenous anastomosis using the ROX coupler system leads to a similar reduction of office and 24-hour ambulatory systolic BP in patients with combined and isolated systolic hypertension.
CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01642498.